Medical Research Council (MRC)
This sponsor has funded 6 studies across 14 countries.
This sponsor has funded 6 studies across 14 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 4238 | Finalised | A RETROSPECTIVE, REAL-LIFE EVALUATION OF THE CARDIOVASCULAR DISEASE RISK ASSOCIATED WITH EXPOSURE TO PHARMACOLOGICAL SMOKING CESSATION INTERVENTIONS... | Yes | No |
| 36059 | Planned | Similarity-based approaches to identifying risk of future asthma attack using UK primary care data | No | No |
| 38362 | Ongoing | The risk of musculoskeletal adverse outcomes after treatment with endocrine blocking treatments for breast cancer (MSKAI) | Yes | No |
| 45026 | Ongoing | COVID-19 in Pregnancy in Scotland COVID-19: vaccine safety analyses in pregnant women (COPS) | Yes | No |
| 47704 | Ongoing | Impact of COVID-19 on Asthma Exacerbations (Asthma Attacks During COVID-19) | No | No |
| 49055 | Planned | Improving detection of associations between congenital anomalies and medicines taken in the first trimester of pregnancy, using data derived... | No | No |
Medical Research Council (MRC)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
Medical Research Council (MRC)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Medical Research Council (MRC)
14 Study countries specified are the following: